[Treatment of scleroderma and dermatomyositis in childhood].
D000293:Adolescent; D000367:Age Factors; D000536:Aluminum Hydroxide / Q000627:therapeutic use; D045930:Anabolic Agents / Q000627:therapeutic use; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use; D003882:Dermatomyositis / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D010396:Penicillamine / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012594:Scleroderma, Localized / Q000188:drug therapy*; D012595:Scleroderma, Systemic / Q000188:drug therapy*
D045930:Anabolic Agents; D007166:Immunosuppressive Agents; D000536:Aluminum Hydroxide; D003520:Cyclophosphamide; D010396:Penicillamine; D011241:Prednisone
Il trattamento della sclerodermia e della dermatomiosite nell'infanzia.